---
title: The Changes in Carotid Plaque Neovascularization After Elovocumab Therapy
nct_id: NCT04423406
overall_status: UNKNOWN
sponsor: Zibo Central Hospital
study_type: OBSERVATIONAL
primary_condition: Carotid Artery Diseases
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04423406.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04423406"
ct_last_update_post_date: 2021-04-21
last_seen_at: "2026-05-12T06:40:46.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Changes in Carotid Plaque Neovascularization After Elovocumab Therapy

**Official Title:** The Changes in Carotid Plaque Neovascularization After Long-term Elovocumab Injection Therapy: A Follow-Up Study by Contrast Enhanced Ultrasonography

**NCT ID:** [NCT04423406](https://clinicaltrials.gov/study/NCT04423406)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 150
- **Lead Sponsor:** Zibo Central Hospital
- **Conditions:** Carotid Artery Diseases
- **Start Date:** 2020-08-01
- **Completion Date:** 2022-02-27
- **CT.gov Last Update:** 2021-04-21

## Brief Summary

150 selected patients will be recruited, who have at least one atherosclerotic plaque in the carotid artery that is thicker than 2.0 mm and which is determined to be uniformly or predominantly echolucent by standard ultrasonography. For each of the plaques, standard ultrasonography will be used to evaluate lesion echogenicity, while contrast-enhanced ultrasonography (CEUS) will be used to perform the visual and quantitative analysis of neovascularization. Each technique will be applied at baseline (at the time of study enrollment) and following 0.5、1 year of Elococumab Injection treatment. During the study, these patients will be treated with Elococumab Injection (1ml:140mg),ih, every two weeks.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 85 Years
- **Sex:** ALL

```
Inclusion Criteria:

* 1\. have at least one atherosclerotic plaque in the carotid artery that is thicker than 2.0 mm and which is determined to be uniformly or predominantly echolucent by standard ultrasonography;
* 2.patients were referred for optimal medical treatment;
* 3.patients agreed to undergo follow-up CEUS at half-year and 1-year interval.

Exclusion Criteria:

* 1.patients had previous history of cerebral thrombosis or cerebral embolism;
* 2.patients were contraindicated to the usage of contrast media;
* 3.image quality of baseline or follow-up CEUS was severely impaired (in presence of severe artifact, non-diagnostic);
* 4.patients withdrew the informed consents during follow-up;
* 5.patients experienced major adverse cerebrovascular events during follow-up;
* 6.patients refused to undergo follow-up CEUS;
* 7.lost follow-up
```

## Primary Outcomes

- **The Changes in Carotid Plaque Neovascularization** _(time frame: June 2020 to December 2021)_ — We will use the time-signal intensity curve to calculate the changes in carotid plaque neovascularization.The time-intensity curve parameters includes: Baseline intensity(BI) and peak intensity (PI).Due to the ultrasound contrast agent, the intra-plaque signal intensity increased. Thus, enhanced intensity (EI) was calculated as follows: EI = PI - BI. EI is a parameter that measures the intensity differences between pre- and post-injections of the intravascular tracer. Relative plaque enhancement (EI-R), measured at the separate peak enhancement point in the blood and plaque, will be calculated as the ratio of enhanced intensity in the carotid artery lumen (EI-L) to the enhanced intensity in the plaque (EI-P) using the following formula: EI-R=EI-L/EI-P.

## Locations (1)

- Zibo Central Hospital, Zibo, Shandong, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.zibo central hospital|zibo|shandong|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04423406.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04423406*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*